ASAM is seeking input from diverse stakeholders on the ASAM Clinical Practice Guideline on Benzodiazepine Tapering. This guideline aims to assist clinicians in helping patients safely taper from their BZD medication, while minimizing withdrawal symptoms.This guideline was developed in partnership with the American Academy of Family Physicians, American Academy of Neurology, the American Academy of Physician Associates, the American Association of Nurse Practitioners, the American Association of Psychiatric Pharmacists, the American College of Medical Toxicology, the American College of Obstetricians and Gynecologists, the American Geriatrics Society, and the American Psychiatric Association.This project is funded by the U.S. Food and Drug Administration (FDA). The deadline to submit comments is July 19, 2024.Instructions for Review1. Download the draft document HERE2. Provide CommentsThis document will be professionally copyedited prior to finalization. Comments will be collected through this survey to facilitate reconciliation of feedback. A preview of the survey can be found here. When providing your comments, please include the page and line number (not a range, just a single number) in the appropriate boxes. If your comment refers to a range of line numbers, you only need to indicate the first line number within the range. To make a general comment about the document as a whole, put 0 for page and line numbers. You can provide up to 100 comments. If you would like to provide additional comments, you can submit the survey again. Feedback must be submitted through this survey to be considered.Note: The system does not allow you to save your progress to return later. Always submit your response before exiting. If you have additional comments at a later time, you can reenter the survey and submit a new response.3. Complete a Disclosure form.You will be redirected to a Disclosure form at the end of this survey. If you are a patient who wishes to remain anonymous, please provide a unique fake name on both this survey and the disclosure form (i.e., not John Doe). Please ensure the name is the same on both forms.If you have any questions, please contact tsafarian@asam.org. Thank you in advance for your participation in this important initiative. We look forward to your feedback. Question Title * What is your name? Question Title * Which of the following best describes your role in addiction treatment? Treatment provider Treatment program Healthcare/system/administrator Health plan/Payer Managed care Policy maker Patient Family member Other (please specify) Question Title * Are you submitting this survey on behalf of collective responses from an organization or agency? Yes No Next
